MedTrace Logo

Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome

NCT05250791 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-06-09

No results posted yet for this study

Summary

This feasibility (small) study aims to see if it is possible to run a large study looking at the effect of lidocaine on large bowel cancer recurrence after surgery in the NHS hospitals.

Conditions

Interventions

DRUG

Lidocaine hydrochloride 2% for injection

An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

DRUG

0.9% sterile Sodium Chloride solution for injection

Administered as lidocaine

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • West Raha, MBChB · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2024-09-15
Completion
2024-09-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05250791 on ClinicalTrials.gov